Research progress in mechanisms of acquired drug resistance and EGFR-targeted therapy tolerance in non-small cell lung cancer

doi:10.19803/j.1672-8629.20240287

Abstract

Abstract: Objective To summarize the progress in treatment of non-small cell lung cancer (NSCLC) with mutations by specific tyrosine kinase inhibitors (EGFR-Tkis) that target the epidermal growth factor receptor (EGFR). Methods Targeted therapies with EGFR currently available were highlighted. The common mechanisms of EGFR-TKIs resistance were elaborated. The characteristics of drug-tolerant persister (DTP) cells and the mechanism of EGFR mutation leading to drug resistance in NSCLC were discussed. Results EGFR-targeted therapies could cause drug-resistance or drug-resistant cells, ultimately leading to tumor recurrence. Conclusion Insights into drug tolerance and underlying causes of resistance can help improve the effectiveness of cancer treatment.

Key words: non-small cell lung cancer(NSCLC), epidermal growth factor receptor(EGFR), targeted therapy, tyrosine kinase inhibitors(EGFR-Tkis), drug tolerance, acquired drug resistance

CLC Number:

R979.1

XIE Sihua, GAO Zhichao, ZHANG Wei, XING Jiahui, LIANG Jingwei, MENG Fanhao. Research progress in mechanisms of acquired drug resistance and EGFR-targeted therapy tolerance in non-small cell lung cancer[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1081-1086.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240287

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I10/1081

References

[1] SUNG H, FERLAY J, SIEGEL RL, et al.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[2] RAMALINGAM SS, VANSTEENKISTE J, PLANCHARD D, et al.Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC[J]. New England Journal of Medicine, 2020, 382(1): 41-50.
[3] ZHAO Y, CHEN G, CHEN J, et al.AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer(NSCLC): an open-label, multicenter, phase II trial[J]. E Clinical Medicine, 2023, 62: 102106.
[4] ORTEGA MA, PEKAREK L, NAVARRO F, et al.Updated views in targeted therapy in the patient with non-small cell lung cancer[J]. J Pers Med, 2023, 13(2): 167.
[5] RODAK O, PERIS-D AZMD, OLBROMSKI M, et al.Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy[J]. Cancers, 2021, 13(18): 4705.
[6] CHHOURI H, ALEXANDRE D, GRUMOLATO L.Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer[J]. Cancers(Basel), 2023, 15(2): 504.
[7] WANG M, HERBST RS, BOSHOFF C.Toward personalized treatment approaches for non-small-cell lung cancer[J]. Nature Medicine, 2021, 27(8): 1345-1356.
[8] GANDULLO-SÁNCHEZ L, OCAÑA A, PANDIELLA A. HER3 in cancer: from the bench to the bedside[J]. J Exp Clin Cancer Res, 2022, 41(1): 310.
[9] SHI Y, LI J, ZHANG S, et al.Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology-mainland China subset analysis of the PIONEER study[J]. PLoS One, 2015, 10(11): e0143515.
[10] RODAK O, PERIS-DÍAZ MD, OLBROMSKI M, et al. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy[J]. Cancers(Basel), 2021, 13(18): 4705.
[11] CHO BC, KIM DW, SPIRA AI, et al.Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial[J]. Nat Med, 2023, 29(10): 2577-2585.
[12] ROTOW J, BIVONA TG.Understanding and targeting resistance mechanisms in NSCLC[J]. Nature Reviews Cancer, 2017, 17(11): 637-658.
[13] HE J, HUANG Z, HAN L, et al.Mechanisms and management of 3rd generation EGFRTKI resistance in advanced nonsmall cell lung cancer[J]. Int J Oncol, 2021, 59(5): 90.
[14] FRANCO NC, GREEN EW, JHAMBA ED, et al.EGFR transactivates RON to drive oncogenic crosstalk[J]. Elife, 2021, 10: e63678.
[15] LEE CK, WU YL, DING PN, et al.Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis[J]. Journal of Clinical Oncology, 2015, 33(17): 1958-1965.
[16] MIYAUCHI E, MORITA S, NAKAMURA A, et al.Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. J Clin Oncol, 2022, 40(31): 3587-3592.
[17] ROSELL R, CARCERENY E, GERVAIS R, et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. The lancet oncology, 2012, 13(3): 239-246.
[18] ZHOU C, WU Y, CHEN G, et al.Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)[J]. Annals of Oncology, 2015, 26(9): 1877-1883.
[19] VASCONCELOS PE, GERGIS C, VIRAY H, et al.EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors[J]. JTO Clinical and Research Reports, 2020, 1(3): 100051.
[20] MORGILLO F, DELLA CCM, FASANO M, et al.Mechanisms of resistance to EGFR-targeted drugs: lung cancer[J]. ESMO Open, 2016, 1(3): e000060.
[21] YANG H, LIU Y, KONG J.Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma[J]. Transl Oncol, 2021, 14(11): 101204.
[22] LEE PH, HUANG YH, LIN H, et al.Histological transformation after acquired resistance to the third-generation EGFR-TKI in patients with advanced EGFR-mutant lung adenocarcinoma[J]. Medicina (Kaunas), 2022, 58(7): 908.
[23] JOHNSON M, GARASSINO MC, MOK T, et al.Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies[J]. Lung Cancer, 2022, 170: 41-51.
[24] HASPINGER ER, AGUSTONI F, TORRI V, et al.Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations[J]. Critical Reviews in Oncology/Hematology, 2015, 94(2): 213-227.
[25] YANG Z, HACKSHAW A, FENG Q, et al.Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis[J]. International Journal of Cancer, 2017, 140(12): 2805-2819.
[26] HERRERA-JUÁREZ M, SERRANO-GÓMEZ C, BOTE-DE-CABO H, et al. Targeted therapy for lung cancer: beyond EGFR and ALK[J]. Cancer, 2023, 129(12): 1803-1820.
[27] JNNE PA, YANG JC, KIM DW, et al.AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J]. New England Journal of Medicine, 2015, 372(18): 1689-1699.
[28] SEQUIST LV, SORIA JC, GOLDMAN JW, et al.Rociletinib in EGFR-mutated non-small-cell lung cancer[J]. New England Journal of Medicine, 2015, 372(18): 1700-1709.
[29] VAN DER STEEN N, CAPARELLO C, ROLFO C, et al. New developments in the management of non-small-cell lung cancer focus on rociletinib: What went wrong?[J]. Onco Targets and Therapy, 2016, 9: 6065-6074.
[30] JANNE PA, AHN MJ, KIM DW, et al.Lba3a phase I study of AZD9291 in patients with EGFR-TKI-resistant advanced NSCLC-updated progression free survival and duration of response data[J]. Annals of Oncology, 2015, 26(Suppl 1): i60.
[31] SORIA JC, OHE Y, VANSTEENKISTE J, et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. New England Journal of Medicine, 2018, 378(2): 113-125.
[32] OXNARD GR, HU Y, MILEHAM KF, et al.Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib[J]. JAMA Oncology, 2018, 4(11): 1527-1534.
[33] THRESS KS, PAWELETZ CP, FELIP E, et al.Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M[J]. Nature Medicine, 2015, 21(6): 560-562.
[34] BLAQUIER JB, ORTIZ-CUARAN S, RICCIUTI B, et al.Tackling osimertinib resistance in EGFR-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2023, 29(18): 3579-3591.
[35] MANSOUR MA, ABOULMAGD AM, ABBAS SH, et al.Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review[J]. RSC Adv, 2023, 13(27): 18825-18853.
[36] RAMALINGAM S, CHENG Y, ZHOU C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study[J]. Annals of Oncology, 2018, 29(Suppl 8): viii740.
[37] YANG Z, YANG N, OU Q, et al.Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients novel resistance mechanisms to osimertinib in NSCLC patients[J]. Clinical Cancer Research, 2018, 24(13): 3097-3107.
[38] ZHANG Y, HE B, ZHOU D, et al.Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report[J]. Onco Targets and Therapy, 2019, 12: 51.
[39] LIN CC, SHIH JY, YU CJ, et al.Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study[J]. The Lancet Respiratory Medicine, 2018, 6(2): 107-116.
[40] PASSARO A, JNNE PA, MOK T, et al.Overcoming therapy resistance in EGFR-mutant lung cancer[J]. Nature Cancer, 2021, 2(4): 377-391.
[41] PIOTROWSKA Z, ISOZAKI H, LENNERZ JK, et al.Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion osimertinib plus BLU-667 in EGFR-mutant NSCLC with acquired RET fusion[J]. Cancer Discovery, 2018, 8(12): 1529-1539.
[42] WENG CH, CHEN LY, LIN YC, et al.Epithelial-mesenchymal transition(EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI[J]. Oncogene, 2019, 38(4): 455-468.
[43] JIA Y, YUN CH, PARK E, et al.Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors[J]. Nature, 2016, 534(7605): 129-132.
[44] TO C, BEYETT TS, JANG J, et al.An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer[J]. Nature Cancer, 2022, 3(4): 402-417.
[45] FERLENGHI F, SCALVINI L, VACONDIO F, et al.A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine[J]. European Journal of Medicinal Chemistry, 2021, 225: 113786.
[46] LIM S, KIM D, JUNG J, et al.1365TiP A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy[J]. Annals of Oncology, 2021, 32: S1035.
[47] LIU X, ZHANG X, YANG L, et al.Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor[J]. Cancer Research, 2019, 79(Suppl 13): 1320.
[48] SPIGEL D, GOTO K, CAMIDGE DR, et al.Abstract P230: a phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor(EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer(NSCLC)[J]. Molecular Cancer Therapeutics, 2021, 20(Suppl 12): P230.
[49] HATA AN, NIEDERST MJ, ARCHIBALD HL, et al.Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition[J]. Nature Medicine, 2016, 22(3): 262-269.
[50] MARINE JC, DAWSON SJ, DAWSON MA.Non-genetic mechanisms of therapeutic resistance in cancer[J]. Nature Reviews Cancer, 2020, 20(12): 743-756.
[51] SHEN S, VAGNER S, ROBERT C.Persistent cancer cells: the deadly survivors[J]. Cell, 2020, 183(4): 860-874.
[52] FISHER RA, GOLLAN B, HELAINE S.Persistent bacterial infections and persister cells[J]. Nature Reviews Microbiology, 2017, 15(8): 453-464.
[53] SADIDA HQ, ABDULLA A, MARZOOQI SA, et al.Epigenetic modifications: key players in cancer heterogeneity and drug resistance[J]. Transl Oncol, 2024, 39: 101821.
[54] RAMIREZ M, RAJARAM S, STEININGER RJ, et al.Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells[J]. Nature Communications, 2016, 7(1): 10690.
[55] ABOUBAKAR NF, OCAK S.Targeting BRAF activation as acquired resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small-cell lung cancer[J]. Pharmaceutics, 2021, 13(9): 1478.
[56] ARASADA RR, SHILO K, YAMADA T, et al.Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC[J]. Nature Communications, 2018, 9(1): 3198.